Share of global active gene therapy and CBIO trials by vector 2022
This statistic shows the distribution of ongoing clinical trials for gene therapies and cell-based immuno-oncology (CBIO) as of end of June 2022, by therapeutic vector. The use of lentiviruses as vector was most common, making up almost half of all such trials.